Drug Profile
Research programme: GPCR targeting therapeutics - Nxera Pharma
Alternative Names: Apelin agonist - Nxera Pharma; Apelin receptor peptide agonist; APLNR peptide agonistLatest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Heptares Therapeutics
- Developer National Heart and Lung Institute; Nxera Pharma; University of Cambridge
- Class Anti-inflammatories; Antiasthmatics; Antihypertensives; Peptides; Small molecules
- Mechanism of Action G protein-coupled receptor agonists; G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Cardiovascular disorders; Immunological disorders; Inflammatory bowel diseases; Pulmonary arterial hypertension
Most Recent Events
- 31 Mar 2024 Sosei Heptares is now called Nxera Pharma
- 28 Apr 2023 No recent reports of development identified for research development in Pulmonary-arterial-hypertension in United Kingdom
- 28 Feb 2021 No recent reports of development identified for research development in Cardiovascular-disorders in United Kingdom